Dr. Clay Siegall, the co-founder, Chairman, and CEO of Seattle Genetics, is known for his ambitious plans in simplified and targeted treatment regimes, especially in cancer therapy. Seattle Genetics has a market value close to $10 billion and employs at least 900 employees with a deep focus on research and marketing with a futuristic vision. “We are growing as a multi-product, global, oncology firm,” declared Dr. Siegall. He further pointed out that the company has many drugs in the pipeline, and he wanted the firm as an innovator in the biotech industry. The flagship drug of the company, Adcetris is an excellent therapy solution for Hodgkin lymphoma approved by the FDA. The expectation created by Seattle Genetics in the industry is huge that its stock price has tripled in the last five years.
Interestingly, under the leadership of Dr. Siegall, the company is very focused on its research, and in 2016, it spent more than $376 million – a 64 percent up from 2014. The biotech firm is basing its research in antibody-drug conjugate (ADC), a target antigen method. These drugs attach to the cancer cells and create toxin inside those cells to kill them. It means that while killing the cancer cells, the therapies do not harm the normal cells. It is a highly effective therapy considering the current radiation therapy or chemotherapy where healthy cells also face the damage from the treatment. Dr. Siegall confirms that as many as 11 more drugs are in the pipeline, and he sees a greater potential for sales with those.
Apart from a dedicated researcher in oncology, Dr. Siegall is also a visionary entrepreneur and brilliant manager. He helped the firm to raise $675 million through private and public financing in 2001 to expand its research activities. It should also be noted that Dr. Siegall led the company to issue its initial public offering as well, in the same year. He holds more than 15 patents and published his papers in at least 70 publications.
Dr. Siegall started his career with the National Cancer Institute, part of National Institutes of Health, in 1988. In 1991, he joined the Bristol-Myers Squibb Pharmaceutical Research Institute as a scientist and worked until 1997. Dr. Siegall left the firm to found Seattle Genetics in the year 1998. He completed his graduation from the University of Maryland in Zoology and gained his Ph.D. from George Washington University in Genetics. Dr. Siegall serves on the director boards of Ultragenyx Pharmaceutical and Alder BioPharmaceuticals.